Validation of EPIC's Readmission Risk Model, the LACE+ Index and SQLape as Predictors of Unplanned Hospital Readmissions
External Validation of EPIC's Readmission Risk Model, the LACE+ Index and SQLape as Predictors of Unplanned Hospital Readmissions: A Monocentric, Retrospective, Diagnostic Cohort Study in Switzerland
1 other identifier
observational
23,116
1 country
1
Brief Summary
The primary objective of this study is to externally validate the EPIC's Readmission Risk model and to compare it with the LACE+ index and the SQLape Readmission model. As secondary objective, the EPIC's Readmission Risk model will be adjusted based on the validation sample, and finally, it´s performance will be compared with machine learning algorithms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 6, 2020
CompletedStudy Start
First participant enrolled
March 10, 2020
CompletedFirst Posted
Study publicly available on registry
March 12, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 10, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2020
CompletedOctober 20, 2020
October 1, 2020
1 month
March 6, 2020
October 18, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (10)
Discrimination at 18 days
For discrimination of the scores under investigation, the area under the receiver operating characteristics curves (AUC) will be calculated.
18 days after index discharge date
Discrimination at 30 days
For discrimination of the scores under investigation, the area under the receiver operating characteristics curves (AUC) will be calculated.
30 days after index discharge date
Calibration at 18 days
For calibration, the Hosmer-Lemeshow goodness-of-fit test will be graphically illustrated by plotting the predicted outcomes by decile against the observations.
18 days after index discharge date
Calibration at 30 days
For calibration, the Hosmer-Lemeshow goodness-of-fit test will be graphically illustrated by plotting the predicted outcomes by decile against the observations.
30 days after index discharge date
Overall Performance at 18 days
Brier Score (The Brier score is a quadratic scoring rule, where the squared difference between actual binary outcomes Y and predictions p are calculated. The Brier score can range from 0 for a perfect model to 0.25 for a non-informative model with a 50% incidence of the outcome.)
18 days after index discharge date
Overall Performance at 30 days
Brier Score (The Brier score is a quadratic scoring rule, where the squared difference between actual binary outcomes Y and predictions p are calculated. The Brier score can range from 0 for a perfect model to 0.25 for a non-informative model with a 50% incidence of the outcome.)
30 days after index discharge date
Clinical usefulness (NRI) at 18 days
Net Reclassification Improvement (NRI): In the calculation of the NRI, the improvement in sensitivity and the improvement in specificity are summed. The NRI ranges from 0 for no improvement and 1 for perfect improvement.
18 days after index discharge date
Clinical usefulness (NRI) at 30 days
Net Reclassification Improvement (NRI): In the calculation of the NRI, the improvement in sensitivity and the improvement in specificity are summed. The NRI ranges from 0 for no improvement and 1 for perfect improvement.
30 days after index discharge date
Clinical usefulness (NB) at 18 days
Net Benefit (NB): NB = (TP - w FP) / N, where TP is the number of true positive decisions, FP the number of false positive decisions, N is the total number of patients and w is a weight equal to the odds of the cut-off (pt/(1-pt), or the ratio of harm to benefit
18 days after index discharge date
Clinical usefulness (NB) at 30 days
Net Benefit (NB): NB = (TP - w FP) / N, where TP is the number of true positive decisions, FP the number of false positive decisions, N is the total number of patients and w is a weight equal to the odds of the cut-off (pt/(1-pt), or the ratio of harm to benefit
30 days after index discharge date
Study Arms (2)
Readmitted inpatients/Cases
Outcome 1: Patients who were readmitted within 18 days of index hospitalization discharge date to the same hospital, with a diagnosis leading to the same Major Diagnostic Group as the index stay (definition according to Swiss Diagnosis Related Groups system, case merger) Outcome 2: Patients with an unplanned readmission within 30 days of index hospitalization discharge date to the same hospital. An unplanned readmission was defined as a readmission through the emergency department.
Non-Readmitted inpatients/Controls
Outcome 1 \& 2: Patients who were not readmitted within 30 days of index hospitalization discharge date.
Interventions
Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
Eligibility Criteria
Inpatients from an acute care hospital in Central-Switzerland
You may qualify if:
- \- All inpatients, aged one year or older (max. 100 years), who were hospitalized either between the 1st of January 2018 and the 31st of December 2018, or between the 23rd of September and the 31st of December 2019 will be included.
You may not qualify if:
- admission/transfer from another psychiatric, rehabilitative or acute care ward from the same institution,
- discharge destination other than the patient's home or
- transfer to another acute care hospital, both being considered as treatment continuation;
- foreign residence,
- deceased before discharge,
- discharged on admission day,
- refusal of general consent, and
- unknown patient residence or discharge destination.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Luzerner Kantonsspitallead
- Universität Luzerncollaborator
Study Sites (1)
Cantonal Hospital of Lucerne
Lucerne, Canton Lucerne, 6000, Switzerland
Related Publications (2)
van Walraven C, Wong J, Forster AJ. LACE+ index: extension of a validated index to predict early death or urgent readmission after hospital discharge using administrative data. Open Med. 2012 Jul 19;6(3):e80-90. Print 2012.
PMID: 23696773BACKGROUNDHalfon P, Eggli Y, Pretre-Rohrbach I, Meylan D, Marazzi A, Burnand B. Validation of the potentially avoidable hospital readmission rate as a routine indicator of the quality of hospital care. Med Care. 2006 Nov;44(11):972-81. doi: 10.1097/01.mlr.0000228002.43688.c2.
PMID: 17063128BACKGROUND
Study Officials
- PRINCIPAL INVESTIGATOR
Aljoscha B. Hwang
University Lucerne (Switzerland)
- PRINCIPAL INVESTIGATOR
Stefan Boes
University Lucerne (Switzerland)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Project Manager & Advanced Analytics Analyst
Study Record Dates
First Submitted
March 6, 2020
First Posted
March 12, 2020
Study Start
March 10, 2020
Primary Completion
April 10, 2020
Study Completion
October 1, 2020
Last Updated
October 20, 2020
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will not share